37 Results Sort by:
EF-Tu Targeting Antibody for Infection Treatment
Application Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections. Key Benefits An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections. A research-grade antibody has been developed with animal data showing the ability to...
Published: 10/13/2023       Contributor(s): Joanna Goldberg, Dina Moustafa
Generation of Vaccines Preventing the Common Cold
Application A new class of vaccines targeting the viruses causing the common cold, rhinoviruses (RV). Key Benefits Capsid-chimeric strains for developing new RV vaccines. Preclinical data with a prototype show the ability to induce a robust capsid-specific immune response. Straightforward and inexpensive vaccine manufacturing process utilizing...
Published: 1/17/2024       Contributor(s): Sujin Lee
RSV Vaccine for Infants and Children
Application Vaccine for Respiratory Syncytial Virus (RSV) in infants and children. Key Benefits A novel vaccine targeting both the F and G proteins of the respiratory syncytial virus (RSV), including its variants. Preliminary data in in mice show the vaccine induced the production of antibodies associated with preventing disease. Potential to...
Published: 3/1/2024       Contributor(s): Larry Anderson, Binh Ha, Heying Sun
BG505 SOSIP Vaccine Elicited Neutralizing Monoclonal Antibodies for HIV
­ Application ELISA Western Blot Immunohistochemistry Specficity HIV-1 BG505 Env protein (clone name: YRK01, YRK02). Subtype Monoclonal antibody. Immunogen HIV-1 BG505 SOSIP Env trimer. Technical Summary HIV-1 envelope glycoprotein (Env) is a membrane protein complex involved in receptor recognition and viral fusion with CD4+ T cells...
Published: 3/1/2024       Contributor(s): Cynthia Derdeyn, Tysheena Charles
Extended Efficacy SARS-COV-2 Vaccine
­ Application A vaccine for SARS-COV-2 that can be used to protect against infection by future forms of Variant-of-Concern (VOC) or other SARS-like coronaviruses. Key Benefits An approach to developing a vaccine that would be effective against future mutations of SARS-COV-2. A vaccine that elicits an immune response to conserved portions...
Published: 4/8/2024       Contributor(s): Chinglai Yang, Ling Ye, Samuel Stampfer, Rui Jin
HIV-1 Clade C Protein Immunogen as HIV-1 Vaccine
Application Novel stabilized HIV-1 Clade C gp140 trimeric immunogen useful as a vaccine. Key Benefits Vaccine for HIV-1 infections. Induces both neutralizing and V1V2 scaffold directed antibody responses. V1V2 scaffold directed antibodies bind to multiple strains of HIV-1 from different clades including Clades B and C. Market Summary HIV-1...
Published: 3/1/2024       Contributor(s): Rama Rao Amara, Sailaja Gangadhara, Tiffany Styles, Anusmita Sahoo
Live Attenuated Zika Virus Vaccines
Application Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines. Key Benefits Reduces neurotropism from Zika virus. High safety and immunogenicity of chimeric vaccines. Market Summary Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 4/10/2024       Contributor(s): Baek Kim
Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular STING Pathway
Application Vaccine formulation of an activator of the stimulator of interferon genes (STING) pathway and saponin adjuvant for enhanced protection of aged population. Key Benefits Significantly improved protective immunity of vaccine in the aged. More efficient than the current methods of influenza vaccination of population 65 years of age or...
Published: 3/1/2024       Contributor(s): Elena Vassilieva, Richard Compans
Virus-Like Particles as RSV Vaccine Candidate
Application Virus-like particle (VLP) vaccine candidate(s) to prevent respiratory syncytial virus (RSV) infection. Key Benefits Candidates may have the most effective anti-viral and anti-inflammatory response. Potentially protects elderly and immunocompromised patients from re-infection with the RSV virus. Efficient, tunable and stable production...
Published: 3/11/2024       Contributor(s): Binh Ha, Larry Anderson, Elizabeth Wright
Trimeric Immunogen for HIV-1 Vaccination
Application Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine. Key Benefits Possible oral administration. Broadly cross-reactive against HIV-1 panel. Promotes antibody responses as both a primary immunogen and boosting immunogen. Market Summary Antiretroviral therapy (ART) has dramatically prolonged...
Published: 9/6/2023       Contributor(s): Rama Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
1 2 3 4